Indian pharmaceutical stocks are reeling from policy jitters after US President Donald Trump signed an executive order on Monday aimed at ramping up domestic drug manufacturing, a move that threatens to undercut India's highly export-driven pharma sector. Stocks such as Aurobindo Pharma, and Lupin (with heavy revenue dependence on the US) have shown signs of weakness.